UroGen Pharma Reports Positive Phase 1 Results For UGN-301 In Non-Muscle Invasive Bladder Cancer
(RTTNews) - UroGen Pharma Ltd. (URGN) announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC).
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
